About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Schizophrenia Clinical Trials in Philadelphia | 153 Studies

Clinical Trials SchizophreniaPhiladelphia

Schizophrenia Clinical Trials in Philadelphia

Find 153 clinical trials for schizophrenia near Philadelphia, Pennsylvania. Connect with research centers in your area.

All Schizophrenia trials nationwide All trials in Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 121-140 of 153 trials

CompletedStudy to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to PaliperidoneThe purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with…NCT00535132·Cerritos, California and 39 others CompletedLong-term Study of Cariprazine in Patients With SchizophreniaThe objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.NCT01104792·Little Rock, Arkansas and 85 others

Schizophrenia Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix San Antonio

Data from ClinicalTrials.govTerms

CompletedStudy to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With SchizophreniaThe primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the…NCT00772005·Little Rock, Arkansas and 38 others

CompletedEfficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative SymptomsTo explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable…NCT00922272·Little Rock, Arkansas and 26 others

CompletedA Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With SchizophreniaThe purpose of this study is to assess the pharmacokinetics, safety, and tolerability of a paliperidone palmitate 3-month formulation in patients with schizophrenia.NCT01559272·Little Rock, Arkansas and 35 others

CompletedBioavailability of LY03004 and Risperdal® Consta®This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with…NCT02091388·Little Rock, Arkansas and 9 others

CompletedA Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent…NCT01192906·Carson, California and 112 others

CompletedeMove - Dance/Movement Therapy StudySchizophrenia is a chronic and severe mental disorder affecting 20 million people throughout the world and is the fourth leading cause of disability in the developed world.NCT05712928·Philadelphia, Pennsylvania

CompletedRelapse Prevention Study in Patients With SchizophreniaThe purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophreniaNCT01291511·Anaheim, California and 62 others

CompletedStudy to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver DiseaseThe purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the…NCT00535145·Cerritos, California and 20 others

TerminatedSPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of SchizophreniaThe primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of…NCT01760889·Miami Springs, Florida and 3 others

CompletedEffect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic PatientsThe purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic…NCT00300963·Little Rock, Arkansas and 19 others

CompletedCAFE Comparison of Atypicals in First Episode of PsychosisThe purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day)…NCT00034892·Stanford, California and 25 others

Not yet recruitingNST-SPARK Open-Label Phase 1 STTR (IGNITE)Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders.NCT07593456·Glen Oaks, New York and 1 other

CompletedAn Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of SchizophreniaThis study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.NCT01175135·Little Rock, Arkansas and 45 others

CompletedA Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic AgentsLurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.NCT01143077·Little Rock, Arkansas and 26 others

CompletedUsing Speech to Monitor Symptom Severity in Arabic Speaking Patients With SchizophreniaBrief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay…NCT05563818·Algiers and 3 others

CompletedIntramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaThe purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with…NCT00705783·Chandler, Arizona and 109 others

RecruitingEffectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and…NCT07379827·Bryant, Arkansas and 54 others

CompletedA Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective DisorderLurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.NCT01143090·Little Rock, Arkansas and 26 others

PreviousPage 7 of 8Next

Other Conditions in Philadelphia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia